CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates a novel approach to cancer therapy by targeting a specific immune checkpoint receptor-ligand interaction. By blocking this interaction, it aims to enhance T cell activity against tumors, potentially improving treatment options for cancer patients.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy over the last decade.
In essence, ICIs block the interaction of immunosuppressive receptors and their ligands, which attenuate T cell activity and the secretion of pro-inflammatory cytokines.
Blocking these inhibitory signals results in the release of immunosuppression and promotes anti-tumor T cell reactivity.Unpublished data from our research group, emerging in collaboration with the biotech company InProTher suggests a nov…
KOBENHAVNS UNIVERSITET
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
